Duparc T - Search Results

1

P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease.

Duparc T, Gore E, Combes G, Beuzelin D, Pires Da Silva J, Bouguetoch V, Marquès MA, Velazquez A, Viguerie N, Tavernier G, Arner P, Rydén M, Langin D, Sioufi N, Nasser M, Cabou C, Najib S, Martinez LO. Duparc T, et al. JCI Insight. 2024 Mar 12;9(8):e175623. doi: 10.1172/jci.insight.175623. JCI Insight. 2024. PMID: 38470490 Free PMC article.

2

Intermittent Fasting Resolves Dyslipidemia and Atherogenesis in Apolipoprotein E-Deficient Mice in a Diet-Dependent Manner, Irrespective of Sex.

Mérian J, Ghezali L, Trenteseaux C, Duparc T, Beuzelin D, Bouguetoch V, Combes G, Sioufi N, Martinez LO, Najib S. Mérian J, et al. Among authors: duparc t. Cells. 2023 Feb 7;12(4):533. doi: 10.3390/cells12040533. Cells. 2023. PMID: 36831200 Free PMC article.

3

Plasma level of ATPase inhibitory factor 1 (IF1) is associated with type 2 diabetes risk in humans: A prospective cohort study.

Pires Da Silva J, Wargny M, Raffin J, Croyal M, Duparc T, Combes G, Genoux A, Perret B, Vellas B, Guyonnet S, Thalamas C, Langin D, Moro C, Viguerie N, Rolland Y, Barreto PS, Cariou B, Martinez LO; MAPT/DSA Group. Pires Da Silva J, et al. Among authors: duparc t. Diabetes Metab. 2023 Jan;49(1):101391. doi: 10.1016/j.diabet.2022.101391. Epub 2022 Sep 26. Diabetes Metab. 2023. PMID: 36174852 Free article.

4

The Multifaceted ATPase Inhibitory Factor 1 (IF1) in Energy Metabolism Reprogramming and Mitochondrial Dysfunction: A New Player in Age-Associated Disorders?

Gore E, Duparc T, Genoux A, Perret B, Najib S, Martinez LO. Gore E, et al. Among authors: duparc t. Antioxid Redox Signal. 2022 Aug;37(4-6):370-393. doi: 10.1089/ars.2021.0137. Epub 2022 Jan 4. Antioxid Redox Signal. 2022. PMID: 34605675 Free PMC article. Review.

5

Metabolic and cardiovascular adaptations to an 8-wk lifestyle weight loss intervention in younger and older obese men.

Vion J, Sramkova V, Montastier E, Marquès MA, Caspar-Bauguil S, Duparc T, Martinez LO, Bourlier V, Harant I, Larrouy D, Moussaoui N, Bonnel S, Vindis C, Dray C, Valet P, Saulnier-Blache JS, Schanstra JP, Thalamas C, Viguerie N, Moro C, Langin D. Vion J, et al. Among authors: duparc t. Am J Physiol Endocrinol Metab. 2021 Sep 1;321(3):E325-E337. doi: 10.1152/ajpendo.00109.2021. Epub 2021 Jul 12. Am J Physiol Endocrinol Metab. 2021. PMID: 34250814 Free article. Clinical Trial.

6

Apilimod alters TGFβ signaling pathway and prevents cardiac fibrotic remodeling.

Cinato M, Guitou L, Saidi A, Timotin A, Sperazza E, Duparc T, Zolov SN, Giridharan SSP, Weisman LS, Martinez LO, Roncalli J, Kunduzova O, Tronchere H, Boal F. Cinato M, et al. Among authors: duparc t. Theranostics. 2021 Apr 19;11(13):6491-6506. doi: 10.7150/thno.55821. eCollection 2021. Theranostics. 2021. PMID: 33995670 Free PMC article.

7

Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.

Ingueneau C, Hollstein T, Grenkowitz T, Ruidavets JB, Kassner U, Duparc T, Combes G, Perret B, Genoux A, Schumann F, Bobbert T, Steinhagen-Thiessen E, Martinez LO. Ingueneau C, et al. Among authors: duparc t. Vascul Pharmacol. 2020 Dec;135:106804. doi: 10.1016/j.vph.2020.106804. Epub 2020 Sep 25. Vascul Pharmacol. 2020. PMID: 32987194

8

A reference measurement of circulating ATPase inhibitory factor 1 (IF1) in humans by LC-MS/MS: Comparison with conventional ELISA.

Genoux A, Duparc T, Ruidavets JB, Ingueneau C, Najib S, Ferrières J, Perret B, Croyal M, Martinez LO. Genoux A, et al. Among authors: duparc t. Talanta. 2020 Nov 1;219:121300. doi: 10.1016/j.talanta.2020.121300. Epub 2020 Jun 30. Talanta. 2020. PMID: 32887042

9

Serum level of HDL particles are independently associated with long-term prognosis in patients with coronary artery disease: The GENES study.

Duparc T, Ruidavets JB, Genoux A, Ingueneau C, Najib S, Ferrières J, Perret B, Martinez LO. Duparc T, et al. Sci Rep. 2020 May 18;10(1):8138. doi: 10.1038/s41598-020-65100-2. Sci Rep. 2020. PMID: 32424189 Free PMC article.

10

Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.

Duparc T, Briand F, Trenteseaux C, Merian J, Combes G, Najib S, Sulpice T, Martinez LO. Duparc T, et al. Am J Physiol Gastrointest Liver Physiol. 2019 Oct 1;317(4):G508-G517. doi: 10.1152/ajpgi.00139.2019. Epub 2019 Aug 28. Am J Physiol Gastrointest Liver Physiol. 2019. PMID: 31460789 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page